What Researchers Did
Researchers conducted a phase II study to evaluate the toxicity, response rates, and time to tumor progression of hyperbaric oxygenation combined with interferon-beta, nimustine hydrochloride, and radiotherapy (HBO/IAR) for supratentorial malignant gliomas.
What They Found
Of 39 patients, 35 completed the therapy with permissible toxicity. Overall response rates (CR + PR%) were 43%, with 50% for glioblastoma and 30% for anaplastic astrocytoma. The median time to tumor progression was 43 weeks overall, 38 weeks for glioblastoma, and 56 weeks for anaplastic astrocytoma.
What This Means for Canadian Patients
This study suggests that combining hyperbaric oxygenation with existing therapies for malignant gliomas could be a tolerable and potentially effective treatment option. Canadian patients with these aggressive brain tumors might benefit from further research into such combined approaches to improve outcomes.
Canadian Relevance
This study was not conducted in Canada and has no direct Canadian connection.
Study Limitations
This phase II study involved a relatively small sample size and lacked a control group, which limits the definitive conclusions that can be drawn.